Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anaptysbio (ANAB) Return on Sales (2016 - 2025)

Anaptysbio's Return on Sales history spans 10 years, with the latest figure at 0.84% for Q4 2025.

  • For Q4 2025, Return on Sales rose 171.0% year-over-year to 0.84%; the TTM value through Dec 2025 reached 0.0%, up 250.0%, while the annual FY2025 figure was 0.0%, 159.0% up from the prior year.
  • Return on Sales reached 0.84% in Q4 2025 per ANAB's latest filing, up from 0.3% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.84% in Q4 2025 to a low of 32.38% in Q1 2022.
  • Average Return on Sales over 5 years is 9.24%, with a median of 4.34% recorded in 2022.
  • Peak YoY movement for Return on Sales: plummeted -3131bps in 2021, then surged 2632bps in 2022.
  • A 5-year view of Return on Sales shows it stood at 30.75% in 2021, then skyrocketed by 86bps to 4.43% in 2022, then fell by -6bps to 4.68% in 2023, then skyrocketed by 81bps to 0.87% in 2024, then surged by 196bps to 0.84% in 2025.
  • Per Business Quant, the three most recent readings for ANAB's Return on Sales are 0.84% (Q4 2025), 0.3% (Q3 2025), and 1.74% (Q2 2025).